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INTRODUCTION
Congenital Factor XIII deficiency (FXIII D) is a rare
genetic bleeding disorder that is inherited in an
autosomal recessive pattern with a frequency of 1 per 2
million individuals in the human population.1 Factor XIII
is a pro-enzyme (composed of 2α2β subunits), activated
to XIIIa by calcium and thrombin in the final step in
coagulation cascade.2 The genes are located on
different chromosomes. The locations are as A subunit
on 6p25-p24, while B subunit on 1q31-q32.1. Activated
factor XIII cross link fibrin and other plasma proteins
(most importantly plasmin inhibitor) to not only form a
clot and hold it in place but also to ensure that clot will
not be digested prematurely.2 Genetic analysis reveals
most cases associated with deficiency of subunit A
located on chromosome 6, while a minority is associated
with subunit B located on chromosome 1.3
Patients with FXIII D usually present at early neonatal
period with prolong umbilical stump bleeding (first and
most characteristic symptom), post circumcision
bleeding or easy bruises during early days and this type
of bleed is fairly common and pathognomic of this
disease.4 Recurrent spontaneous abortions and
menorrhagia have also been reported in early
pregnancy.4,5 Typically, bleeding symptoms occur hour
or days after trauma.1 The most threatening and
devastating complication with high mortality in these
patients is intracranial bleeding.6,7 The diagnosis can be
delayed in FXIII D as the standard coagulation profile is
normal in these patients.4 Being a rare bleeding
disorder, it needs a high index of suspicion as
transfusion with blood, plasma and other blood products
prior to proper investigations can contribute in delayed
diagnosis in FXIII D.7
Most of the autosomal recessive disorders are
associated with consanguinity and that is why the
incidence of severe congenital FXIII D is increased in
populations where consanguineous marriages are
common.8 Hussain et al. reported that 60% of all
Pakistani marriages were consanguineous,9 therefore,
the diseases having familial tendency may be
associated with higher prevalence than in other
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countries.10 Although congenital deficiency is the
commonest, some acquired causes of deficiency may
also be seen in other diseases i.e. liver diseases,
disseminated intravascular coagulation, and renal
insufficiency and with anti-tuberculosis therapy.11,12
The objective of this case series was to describe the
baseline of demographic and clinical features along with
the clinical outcome of 10 pediatric patients with
congenital FXIII D, admitted in a tertiary care hospital of
Karachi, Pakistan.
METHODOLOGY
It was an observational descriptive case series. The
study participants included all patients aged one year to
15 years, who were admitted and discharged from The
Aga Khan University Hospital with the discharge
diagnosis of FXIII D, from January 1996 till December
2006.  Patients were identified by using coded discharge
records with the diagnosis of coagulation/factor
deficiency, as there is no specific identity available in
ICD book. ICD9 CM 286.3 was used for identification of
study patients. Diagnosis were confirmed by performing
clot solubility tests in 5 mol/L urea, a qualitative test for
diagnosis of FXIII deficiency; those found positive were
labelled as factor XIII deficient. 
Inclusion criteria were cases selected by searching
coded discharge records factor XIII deficiency, aged
upto 15 years with FXIII D confirmed at the centre.
Exclusion criteria were patients with acquired FXIII D.  
Data was abstracted on a pre-specified proforma.
Features including gender, age at presentation,
presenting complaints, family history, consanguinity, and
management at hospital, complications and their follow-
up visits were recorded. SPSS version 13 was used for
data entry and analysis. Mean and standard deviation of
age at presentation and hospital stay was calculated,
while frequency percentage of gender, consanguinity in
parents, family history of bleeding disorder or FXIII D,
and complications were recorded.
RESULTS
Ten patients were identified as cases, during the study
period, out of 56 patients with bleeding coagulation
disorder. Males and females were equal (5 each). Nine
patients were less than 5 years (mean age 27 months).
Five patients were infants; while 3 were neonates. Easy
bruisability and hematoma at different sites were the
presenting features to the hospital in 8 patients (Table I).
One of them presented with excessive cry, irritability and
bulging fontanel, while delayed umbilical stump bleeding
was present in 2 patients. Past history revealed that
almost all had history of prolonged umbilical bleeding.
Five patients had been hospitalized previously with
some bleeding complaint. Consanguinity in parents was
found in 8 patients. Two patients had history of FXIII D
in siblings, while 2 had history of prolonged bleeding of
unknown cause in the family.  Bruises (7 patients) and
pallor (5 patients) were the major clinical findings at
presentation. Two patients had intracranial bleeding,
proved on neuroimaging, and were managed with fresh
frozen plasma, cryoprecipitate, packed red blood cell
transfusions and craniotomy. Two patients had large
hematoma on body, managed conservatively. Platelets
count, and initial coagulation screen (PT, APTT and BT)
were found normal in all patients, while a clot solubility
tests in 5 mol/L urea test for FXIII deficiency were found
to be positive.  All the rest were managed with plasma
and cryoprecipitate transfusion, while 6 required packed
cell transfusion during the hospital stay. All patients
were discharged alive (average length of stay 2.6 ± 2.4
days) and followed-up in outpatient clinic. Nine patients
were alive and well with no major bleeding episodes at
one year of follow-up on prophylactic monthly
cryoprecipitate infusion, while one lost the follow-up.
DISCUSSION
Inherited FXIII D is a rare autosomal recessive disorder
affecting approximately one out of 1-3 million people.3 It
was first described by Duckert et al. in 1960 in a 7-year -
old Swiss boy.13 This disorder is so rare that to-date only
300 patients have been identified.1 The maximum
number of patients were identified in Japan (53
patients).1 Although a rare disorder because of serious
manifestations i.e. intracranial bleeding and recurrent
abortions, it has been highlighted more than any other
bleeding disorders.5
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Table I:  Demographic features and clinical findings of factor XIII 
deficient patients.
Characteristics                                    Patients (n = 10) (%)
Age in months (mean, SD) 27+ 20
Neonates 3 (30%)
Infants 5 (50%)




Easy bruisability 8 (80%)
Hematoma 8 (80%)
Delayed umbilical bleeding 2 (20%)
Irritability / bulging fontanel 1 (10%)
History of umbilical cord bleeding 10 (100%)
Previous hospitalization 5 (50%)
Consanguineous marriage in parents 8 (80%)
Factor XIII deficiency in family and/or 
prolonged bleeding history 4 (40%)
Hemoglobin on arrival (mean, SD) 8.4 +1.6
PT, APTT and BT clinical outcome                    Normal
Alive (at discharge) 10 (100%)
Alive (at 1 year follow-up) 9* (90%)
Length of stay (days) 2.6 + 2.4
*One patient lost to follow-up
FXIII D has three subtypes.13 Type I deficiency has both
subunit A and subunit B. Type II has no activity of
subunit A and reduced to normal activity of subunit B.
Type III has normal subunit A and deficiency of subunit
B. Literature review showed 2 case series from
Pakistani population, one reported 13 while the second
reported 6 patients.10,15 The most common subtype in
our country is still not identified, but Anwar et al. reported
subunit A deficiency as the commonest with different
codon mutations in a case series.15
Deficiency of factor XIII leads to an unstable clot
formation, which is dissolvable in plasma and ultimately
leads to bleeding tendency. Most patients in this series
presented with bleeding from different sites of body and
easy bruisability. Another important feature is prolonged
umbilical stump bleeding or delayed cord separation; 2
neonates presented with prolonged umbilical cord
bleeding and almost all others had prior history of
prolonged umbilical stump bleeding. The findings are
comparable with other studies reported in adults
showing subcutaneous bleeding (57%), followed with
umbilical cord bleeding (56%), muscle hematoma (49%)
and intracranial bleeding (34%) to be the major clinical
presentation.16 Most  of the patients presented early in
their life, which is supported by literature.1,4,6,15 
Despite the fact that half of the patients sought some
medical attention for a bleeding episode prior to
presentation, they were not worked up for any bleeding
disorder or coagulation abnormality, as this is one of the
commonly reported phenomena in the literature.1,15
Prolonged umbilical bleeding is a hallmark of FXIII D in
neonates.8,17 All the patients had history of prolonged
umbilical bleeding, while one had prolonged caput
succedaneum, which is also reported in the literature.18
Any neonate with this complaint should be screened for
FXIII D and other bleeding disorders once sepsis has
been ruled out, especially, if there is consanguinity or
family history of bleeding disorder. 
Consanguinity plays a major role in transmission of
disease, as in all autosomal recessive disorders, the
incidence is more among inter-family marriages. Various
case series reported all of their patients being
consanguineous and presenting early in life with
bleeding diathesis.1,9,15 Inter-family marriages are fairly
common in Pakistan, causing high prevalence of this
disease in our country.9,15 In this study, 8 children had
consanguinity in the family. Family history of bleeding
disorder and known FXIII D in siblings were not revealed
earlier which may have lead to delayed diagnosis. Two
patients had family history of some bleeding tendency,
while FXIII D was positive in other 2. 
Intracranial hemorrhage (ICH) is more associated with
FXIII D as compared to other bleeding disorders. ICH
may occur spontaneously or after minor trauma and is
associated with mortality and morbidity with long-term
sequelae. Two patients presented with Intracranial
Bleed (ICB) and survived with no neurological sequelae.
Association of ICB and mortality is as high as 25%.12
It is important not only to identify early but also to ensure
that these children be started on prophylactic therapy
(regular transfusion of plasma or cryoprecipitate or
factor XIII concentrate) so as to prevent a very high risk
of spontaneous or acquired intracranial bleeding and
its consequences.19 Plasma half-life of factor XIII is long
ranging from 5-9 days, thus regular monthly
transfusions are required to optimize its level.
Based on our findings, recommendations can be
formulated: Children born with a sibling having FXIII D or
with family history of bleeding diathesis should be
screened. Patient once diagnosed with FXIII D needs to
start on prophylactic therapy of regular transfusion of
plasma or cryoprecipitate, so serious manifestations i.e.
ICH can be prevented. It is also important to perform
prenatal screening. 
It is also important to develop support groups to
increase awareness and help the patients and their
families who require regular transfusion of blood and
blood products.  Currently, a new factor XIII database
website (http://f13-database.de) is established having
information regarding proteins, mutation and
polymorphism of FXIII D. It also provides useful
information about demographic situation, diagnosis
and treatment possibilities and genotype-phenotype
correlation in patients with inherited FXIII D.16
CONCLUSION
FXIII D is a rare genetic disorder, but it is seen relatively
common in Pakistan because of inter-marriages. Thus,
in children with history of bruising, prolonged umbilical
bleeding along with any family history of bleeding or
easy bruisability and consanguinity in parents, it is
essential to rule out FXIII D.
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